Curated News
By: NewsRamp Editorial Staff
March 12, 2026
Helus Pharma Appoints Jill Conwell as Chief People Officer Amid Clinical Advancements
TLDR
- Helus Pharma appoints Jill Conwell as chief people officer, leveraging her 20+ years of life sciences leadership to strengthen talent strategy during clinical advancement and growth phases.
- Helus Pharma appoints Jill Conwell as chief people officer to guide organizational development and talent strategy as the company advances its Phase 3 and Phase 2 clinical programs.
- Helus Pharma's appointment of Jill Conwell supports its mission to develop novel treatments for depression and anxiety, aiming to improve mental health care globally.
- Helus Pharma appoints Jill Conwell, a veteran from Aclaris and Shire, as chief people officer to help scale the company during its clinical development of novel mental health drugs.
Impact - Why it Matters
This appointment signals Helus Pharma's strategic focus on scaling its operations as it advances promising clinical trials for mental health treatments. With mental health disorders affecting millions globally and existing treatments often having limitations in efficacy or side effects, the development of novel serotonergic agonists represents a potential breakthrough. Conwell's expertise in talent development and organizational strategy could accelerate the company's ability to bring these therapies to market, potentially offering new options for patients with depression and anxiety who haven't responded to conventional treatments. The company's progress in Phase 3 trials with FDA Breakthrough Therapy designation suggests these developments could soon translate into tangible treatment alternatives, making this leadership move relevant for patients, healthcare providers, and investors in the mental health space.
Summary
Helus Pharma, a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs) for mental health conditions, has appointed Jill Conwell as its new chief people officer. Conwell brings over two decades of leadership experience from prominent life sciences firms including Aclaris Therapeutics, Idera Pharmaceuticals, and Shire Pharmaceuticals, where she specialized in organizational strategy, talent development, and corporate communications. Her appointment comes as Helus Pharma advances its clinical programs, including HLP003 in Phase 3 trials for major depressive disorder and HLP004 in Phase 2 for generalized anxiety disorder, both targeting significant unmet needs in mental health treatment.
The company, operating under the commercial name Helus Pharma while being the operating entity of Cybin Inc., focuses on developing synthetic molecules designed to activate serotonin pathways to promote neuroplasticity. With Breakthrough Therapy Designation from the U.S. Food and Drug Administration for HLP003, Helus Pharma aims to revolutionize mental health care through durable improvements. The announcement was disseminated via PsychedelicNewsWire, part of the Dynamic Brand Portfolio within IBN, which provides extensive distribution and communication services for the psychedelics sector.
For more details, readers can visit the full press release at https://ibn.fm/undtF or explore the company's updates at https://ibn.fm/HELP. Helus Pharma maintains a strong online presence through its website www.helus.com and social media platforms, emphasizing its commitment to transparency and engagement in the rapidly evolving field of psychedelic-inspired therapeutics.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Helus Pharma Appoints Jill Conwell as Chief People Officer Amid Clinical Advancements
